PTC/SB/08a (08-03 )
Approved for use through 97/31/2006, ONE 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number	
	Filing Date	
	First Named Inventor Koji	Wakiyama
	Art Unit	
	Examiner Name	
	Attorney Docket Number	40550

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code1 Issue Date Name of Patentee or Applicar of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1									
If you wisl	n to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion		Name of Patentee or Applicant Re		Columns,Lines whe int Passages or Rele s Appear	
	1									
If you wis	to a	dd additional U.S. Publi		,				d button		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or  v	Pages,Columns,Line where Relevant Passages or Releval Figures Appear	74
	1	2001-227914	JP			2001-08-24	Matsushita Electric Co Ltd	Ind		
	2	2000-259817	JP			2000-09-22	Oki Electric Ind Co	Ltd		
	3	2001-257928	JP			2001-09-21	Technosonic KK			

# Application Number Filing Date Filing Date Filing Date First Number Invalid Market May Watelyama Art Unit Examiner Name Attorney Docket Number | Application Number | Application

	4	2002-094865	JP		2002-03-29	Matsushita Electric Ind Co Ltd		
	5	2003-141517	JP		2003-05-16	Matsushita Electric Ind Co Ltd		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city ancilor country where published.						Тŝ	
	1 International Search Report dated March 29, 2005 taken from PCTUP2004018951 filed December 17, 2004 (2 pages).							
If you wis	h to a	dd additional non	patent literature docu	ment ci	tation informati	ion please click the Add I	button Add	
			Đ	CAMINE	R SIGNATUR	E		
Examiner	Signa	ture				Date Considered		
SEVANDED LIVE IN A SECOND CONTRACTOR OF THE SE								

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at swer\_USPTO\_GOV or MPEP 601.04. \* Enter office that issued the document, by the hove-left own (WIPO Standard ST3.). \* For Lapranese patent documents, the advantage on the parent of the Emperor want precedes the seath number of the patent of the parent of the parent of the patent own precedes the seath number of the patent own of the parent of the patent own of the parent own precedes the patent patent of the patent own precedes the patent patent of the patent patent

# Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) First Numed Inventor Kay Wakiyama Art Unit Examiner Name Attorner Oochet Number | 40050

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and	d 1.98 to make the appropriate selection(s):	
----------------------------	--	--

That each item of information contained in the information disclosure statement was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e/t1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/jeffrey j sopko/	Date (YYYY-MM-DD)	2006-06-08			
Name/Print	Jeffrey J. Sopko	Registration Number	27676			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2311-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.